April 4 (Reuters) - Britain's competition watchdog said Theramex's purchase of European rights to two of Viatris'
women's healthcare products ranges could lead to higher prices and lesser options for hormone replacement therapy treatments.
Drugmaker Viatris agreed to sell its rights to Duphaston and Femoston product ranges to London-based Theramex in October.
(Reporting by Prerna Bedi in Bengaluru; Editing by Shinjini Ganguli)
((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments